Reports Q3 revenue $3.26M, consensus $3.49M. “We are well-resourced to advance our portfolio of innovative drug candidates for the treatment of neurodegenerative diseases, with a sharpened focus on our differentiated Alector (ALEC) Brain Carrier platform,” said Arnon Rosenthal, Chief Executive Officer of Alector. “ABC represents an important driver of innovation, with the versatility to deliver antibodies, enzymes and nucleic acid to the brain. Our ABC-enabled programs have demonstrated robust brain penetration through peripheral dosing, favorable safety, and good pharmacokinetics. We are advancing AL137, our ABC-enabled anti-amyloid beta antibody, AL050, our ABC-enabled GCase enzyme replacement therapy, and ADP064, our ABC-enabled Tau siRNA, toward IND-enabling studies, with IND submissions targeted in 2026 and 2027.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment
- Alector’s Strategic Potential in Biotechnology: Buy Rating Justified Despite Price Target Reduction
- Alector price target lowered to $5 from $10 at H.C. Wainwright
- Alector downgraded to Neutral from Buy at BTIG
- Alector downgraded to Market Perform from Outperform at William Blair